There is a real consensus that new antibiotics are urgently needed and are the best chance
for combating antibiotic resistance. The phylum Actinobacteria is one of the main producers …

Natural Products (NP) are essential for the discovery of novel drugs and products for
numerous biotechnological applications. The NP discovery process is expensive and time …

Streptomyces are a large and valuable resource of bioactive and complex secondary
metabolites, many of which have important clinical applications. With the advances in high …

Covering: up to 2022 Streptomyces are ubiquitous in terrestrial and marine environments,
where they display a fascinating metabolic diversity. As a result, these bacteria are a prolific …

Actinobacteria constitute prolific sources of novel and vital bioactive metabolites for
pharmaceutical utilization. In recent years, research has focused on exploring actinobacteria …

The increasing demand for new bioactive compounds to combat the evolution of multi-drug
resistance (MDR) requires research on microorganisms in different environments in order to …

In the struggle with antibiotic resistance, we are losing. There is now a serious threat of
moving into a postantibiotic world. High levels of resistance, in terms of both frequency and …

The heterologous expression of natural product biosynthetic gene clusters (BGCs) has
traditionally been used as a genetic platform to link various natural product chemotypes to …

Species of the genus Streptomyces are known for their ability to produce multiple secondary
metabolites; their genomes have been extensively explored to discover new bioactive …

Covering: 2010 to 2020 Over the last few decades, Streptomyces have been extensively
investigated for their ability to produce diverse bioactive secondary metabolites. Recent …